DBTECH

Dear Reader, As per your request, you have been removed from our mailing list for ETtech Unwrapped Get all the updates from the world of business straight to your inbox Getting bigger and stronger. 4 million+ subscribers MANAGE ALL NEWSLETTERS » Daily Newsletter

VIEW IN BROWSER | SUBSCRIBE TUE, OCT 15, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon and happy Tuesday! To no surprise, expanding Medicare coverage of costly weight loss drugs could come at a steep cost for the federal government.  Allowing Medicare to cover obesity medications would increase federal spending by about $35 billion from 2026 to 2034, according to an analysis released by the U.S. Congressional Budget Office last week.  The federal costs for covering those drugs would grow from $1.6 billion in 2026 to $7.1 billion in 2034, the CBO said.  The analysis is all hypothetical, and comes as drugmakers and advocacy groups push for the government to expand coverage of – and give more seniors access to – the highly popular treatments. Those include GLP-1s for obesity such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which both carry hefty price tags of r